LOXL partnership & Phase 2 readout of the Nash trial are still on track to be released this Quarter ....I think this pure Goldmine has the potential to move closeto $1 on positive outcome .STRONG BUY
New Presentataion
https://www.asx.com.au/asxpdf/20191125/pdf/44bwsrxqmg2g12.pdf
Key catalysts targeted for 2019/2020 -- Pharmaxis value driving events
1.Boehringer Ingelheim acquired AOC3 inhibitor to report clinical proof of concept
Phase 2a NASH study in 114 patients for 3 months -last patient last visit complete.Phase 2a clinical trial result and commercial assessment to progress to Phase 2b due from BI -Q4 2019
Phase 2a diabetic retinopathy study in 100 patients for 3 months ->50% recruitedClinical and commercial assessment due from BI -mid 2020
2.LOXL2 anti fibrotic program
Partnering process to conclude -H2 2019
3.Mannitol Business (Aridol & Bronchitol) to turn profitable in CY 2020
US -FDA to complete review H1 2020; if approved -launch milestone US$10m
PXS=MC $75 M --2 Marketed Products --MEGA Milestones IMMINENT =Disallowed or Buyout Gem, page-9
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
